Core Viewpoint - Doning Biotechnology has submitted an application for listing on the Hong Kong Stock Exchange, aiming to become a mainboard listed company, with Morgan Stanley and Huatai International as joint sponsors [1] Company Overview - Established in 2005, Doning Biotechnology is rooted in the life sciences industry, providing comprehensive solutions for the development and commercialization of biopharmaceutical products [1] - The company operates two main business lines: 1. Bioprocess Solutions, offering a wide range of products including reagents, consumables, and equipment that cover all major steps of bioprocessing 2. Laboratory Products and Services, providing products for laboratory R&D and bioprocess solutions, including technical development, testing, and validation services [1] Financial Performance - In the first nine months of the previous year, the company reported revenue of 658 million yuan, representing a year-on-year increase of 19.39% - The profit attributable to shareholders was 21.604 million yuan [1]
多宁生物科技向港交所提交上市申请
Ge Long Hui A P P·2026-01-18 15:14